In the fourth quarter of 2009, SciClone announced the enrollment of its first patient in a phase 2 trial of SCV-07 for the treatment of hepatitis C (also known as HCV). This multicenter, multidose, open-label study is designed to evaluate the safety and immunomodulatory effects of SCV-07 as a monotherapy or in combination with ribavirin in non-cirrhotic patients with genotype 1 chronic HCV who have relapsed after at least 44 weeks of treatment with pegylated interferon and ribavirin.

SciClone Pharmaceuticals is also enrolling patients in its phase 2, multi-center, randomized, double-blind, placebo-controlled study to examine the effect of SCV-07 in the delay to onset of oral mucositis (OM) in patients receiving radio-chemotherapy for the treatment of head and neck cancer. SCV-07 is an investigational drug given subcutaneously.

Webcast SciClone Pharmaceuticals SciClone Pharmaceuticals Investor Call on SciClone's SCV-07 phase 2 Study in Oral MucositisSci July 15, 2009 SciClone Pharmaceuticals SciClone Pharmaceuticals Stephen Sonis, DMD, DMSc and professor of oral medicine SciClone Brigham and Women's Hospital, Boston, MA SciClone Pharmaceuticals Hosted by: ThinkEquity, LLC

About SCV-07

SCV-07 is a small molecule which stimulates the immune system through inhibition of STAT3-dependant signaling and the resulting effects on T-helper 1 cells, which are essential for clearance of viral infections. SCV-07 has shown a good safety profile in several early stage clinical trials in healthy volunteers and subjects with HCV at various doses.

SCV-07 is protected by composition of matter patents as well as multiple method of treatment patents. SciClone has exclusive worldwide rights to SCV-07 outside of Russia, where the molecule has recently been approved for stimulation of depressed immune systems.

Related Publications and References